Development Programs

Infectious Disease

Preclinical
Phase 1
Phase 2
Phase 3
Hepatitis B Prophylaxis
Sci-B-Vac®

VLP

Approved for use and commercially-available in Israel

100%

Phase 3 Complete (US, EU, CAN)

100%
Hepatitis B Therapeutic
VBI-2601

VLP

Phase 1b/2a

55%
Cytomegalovirus Prophylaxis
VBI-1501

eVLP

Phase 1 Complete

52%
Pan-Coronavirus Prophylaxis
VBI-2901

eVLP

Preclinical

15%
Zika Virus Prophylaxis
VBI-2501

eVLP

Preclinical

15%

Immuno-Oncology

Preclinical
Phase 1
Phase 2
Phase 3
Glioblastoma Multiforme
VBI-1901

eVLP

Phase 1/2a

55%
Medulloblastoma
VBI-2701

eVLP

Preclinical

25%